Ironwood Pharmaceuticals Reports Strong Q3 2026 Results and Raises Full-Year Guidance
Ironwood Pharmaceuticals (IRWD) delivered robust third-quarter 2026 financial results, characterized by a significant increase in total revenue to $133 million compared to $122.1 million in the prior year. The company achieved record Adjusted EBITDA of $97.9 million, driven by strong commercial performance and improved brand efficiency. LINZESS U.S. net sales reached $324.9 million, fueled by a 4.9% increase in prescription demand. Reflecting sustained momentum, management raised its full-year guidance for both total revenue ($485 million to $510 million) and LINZESS sales ($1.2 billion to $1.25 billion). The company also demonstrated disciplined capital management by making $60 million in principal debt repayments, aiming to reduce outstanding debt to less than $300 million by year-end to support the upcoming apraglutide launch.
Tickers: $IRWD
Topics: EBITDA Guidance Increase Net Income Prescription Demand Revenue Growth